Drugs / ZX-8177
last change Dec 2025 re-read 3 minutes ago

ZX-8177

Developed for
cancer
Investigated by
Nanjing Zenshine Pharmaceuticals

Trials 1

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT07310134 Dec 2025 → Nov 2026 expected cancer Nanjing Zenshine Pharmaceuticals Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ZX-8177 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07310134 ↗